Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9KNJT)

• Drug Name: Vobarilizumab Drug Info
• Synonyms: ALX-0061

Indication

Disease Entry	ICD 11	Status	REF
Rheumatoid arthritis	FA20	Phase 2	[1]
Systemic lupus erythematosus	4A40.0	Phase 2	[2]

• Cross-matching ID: TTD Drug ID: DM9KNJT

Molecule-Related Drug Atlas

Drug(s) Targeting Serum albumin (ALB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gadobenate Dimeglumine	DM4VAOG	Schizophrenia	6A20	Approved	[4]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[5]
Oxyphenbutazone	DMPZS7U	Arthritis	FA20	Approved	[6]
Iodipamide	DMXIQYS	Gallbladder disease	DC11.3	Approved	[7]
SPI-1005	DM6XFHS	Reperfusion injury	ND56.Z	Approved	[8]
Gadofosveset	DM5V9U1	Imaging	QA0B	Approved	[9]
Albumin Human	DM5JTPU	Hypoalbuminemia	5C53.2	Approved	[10]
Bismuth	DMTKU46	Diarrhea	ME05.1	Approved	[11]
EVANS BLUE	DM5GT1M	Abdominal aortic aneurysm	BD50.4	Approved	[12]
Activated recombinant FVII-albumin fusion protein	DMKY9GI	Hemophilia	3B10.0	Phase 2/3	[13]

Drug(s) Targeting Interleukin 6 receptor (IL6R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tocilizumab	DM7J6OR	Giant cell arteritis	4A44.2	Approved	[14]
Sarilumab	DMOGNXY	Rheumatoid arthritis	FA20	Approved	[10]
Sirukumab	DMK8AQP	Cutaneous lupus erythematosus	EB5Z	Phase 3	[15]
SAR153191	DMXAO4J	Ankylosing spondylitis	FA92.0	Phase 3	[16]
SA-237	DM7F2VG	Encephalopathy	8E47	Phase 3	[17]
ALX-0061	DMO1VHC	Autoimmune diabetes	5A10	Phase 2	[18]
SBP-002	DM9F7R0	Melanoma	2C30	Terminated	[10]
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[19]
FM-101	DMXK6EI	Multiple myeloma	2A83	Investigative	[15]
Sant7	DM9CV4P	Multiple myeloma	2A83	Investigative	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin 6 receptor (IL6R)	TT0E5SK	IL6RA_HUMAN; IL6RB_HUMAN	Inhibitor	[3]
Serum albumin (ALB)	TTFNGC9	ALBU_HUMAN	Inhibitor	[3]

References

• [1] ClinicalTrials.gov (NCT02518620) An Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of ALX-0061 in Subjects With Rheumatoid Arthritis. U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT02437890) A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus. U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of Ablynx.
• [4] Protocol design for high relaxivity contrast agents in MR imaging of the CNS. Eur Radiol. 2006 Nov;16 Suppl 7:M3-7.
• [5] Some properties of the interaction between 2,2'-diselenadibenzoic acid and serum albumins. J Pharm Biomed Anal. 2005 Sep 1;39(1-2):263-7.
• [6] Effect of albumin conformation on binding of phenylbutazone and oxyphenbutazone to human serum albumin. J Pharm Sci. 1982 Feb;71(2):241-4.
• [7] Determining binding sites of drugs on human serum albumin using FIA-QCM. Biosens Bioelectron. 2008 Sep 15;24(1):48-54.
• [8] Transport of ebselen in plasma and its transfer to binding sites in the hepatocyte. Biochem Pharmacol. 1994 Sep 15;48(6):1137-44.
• [9] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [10] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [11] Competitive binding of bismuth to transferrin and albumin in aqueous solution and in blood plasma. J Biol Chem. 2001 Mar 23;276(12):8829-35.
• [12] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [13] ClinicalTrials.gov (NCT01542619) A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers. U.S. National Institutes of Health.
• [14] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2310).
• [16] Pharma & Vaccines. Product Development Pipeline. April 29 2009.
• [17] IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA. MAbs. 2013 March 1; 5(2): 178-201.
• [18] The preclinical pharmacology of the high affinity anti-IL-6R Nanobody ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015 May 20;17:135.
• [19] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [20] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.